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Abstract
Aristolochic Acid (AA) nephropathy (AAN) is a progressive tubulointerstitial nephritis charac-
terized by an early phase of acute kidney injury (AKI) leading to chronic kidney disease
(CKD). The reduced nitric oxide (NO) bioavailability reported in AAN might contribute to
renal function impairment and progression of the disease. We previously demonstrated that
L-arginine (L-Arg) supplementation is protective in AA-induced AKI. Since the severity of
AKI may be considered a strong predictor of progression to CKD, the present study aims to
assess the potential benefit of L-Arg supplementation during the transition from the acute
phase to the chronic phase of AAN. C57BL/6J male mice were randomly subjected to daily
i.p. injections of vehicle or AA for 4 days. To determine whether renal AA-induced injuries
were linked to reduced NO production, L-Arg was added to drinking water from 7 days
before starting i.p. injections, until the end of the protocol. Mice were euthanized 5, 10 and
20 days after vehicle or AA administration. AA-treated mice displayed marked renal injury
and reduced NO bioavailability, while histopathological features of AAN were reproduced,
including interstitial cell infiltration and tubulointerstitial fibrosis. L-Arg treatment restored
renal NO bioavailability and reduced the severity of AA-induced injury, inflammation and
fibrosis. We concluded that reduced renal NO bioavailability contributes to the processes
underlying AAN. Furthermore, L-Arg shows nephroprotective effects by decreasing the
severity of acute-to-chronic transition in experimental AAN and might represent a potential
therapeutic tool in the future.
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Introduction
Aristolochic acid (AA) nephropathy (AAN) is a progressive tubulointerstitial nephritis of toxic
origin that leads to end-stage renal disease (ESRD). The term AAN includes any form of toxic
interstitial nephropathy that is caused either by ingestion of plants containing AA as part of
traditional phytotherapies (known as “Chinese herbs nephropathy”), or by environmental con-
taminants in food (Balkan endemic nephropathy)[1–3]. Although products containing AA
have been banned in most countries, AAN cases remain regularly reported all over the world
and its incidence is probably highly underestimated given the weak awareness of the disease
[1]. Clinically, AAN is characterized by a progressive atrophy of proximal tubules and a typical
corticomedullary gradient of interstitial fibrosis[4]. Moreover, a strong correlation between
AA intoxication and urothelial carcinoma has been described[5] and AA are now classified
among the highly human carcinogenic substances by the World Health Organization Interna-
tional Agency for Research on Cancer[6].
These past decades, AAN animal models have been developed by our group[7–10]. A
biphasic evolution of renal function and morphological alterations has been demonstrated[8].
First, an early phase of acute kidney injury (AKI) occurred with necrosis of proximal tubular
epithelial cells (PTEC), leading to a later phase of chronic kidney disease (CKD) characterized
by development of progressive interstitial fibrosis[8] with interstitial inflammation[11,12].
Moreover, defective activation of antioxidative enzymes[13,14], mitochondrial damage[15],
fibroblast activation[9] and hypoxic renal injury[16–18] were demonstrated to play a crucial
role in AAN physiopathology. However, the mechanisms underlying AAN progression still
require investigation in order to develop effective therapeutic strategies.
Nitric oxide (NO) is known to be a key regulator in several physiological processes. Particu-
larly in the kidney, NO is involved in many mechanisms such as the regulation of renal hemo-
dynamic and the maintenance of sodium and water homeostasis[19]. Decreased NO
bioavailability has been demonstrated in several renal disease that could contribute to progres-
sion in chronic stage[20]. We recently demonstrated that NO bioavailability was reduced in a
mouse model of AA-induced AKI. Moreover, L-arginine (L-Arg) supplementation allowed to
restore NO bioavailability which, in turn, improved renal function, reduced oxidative stress,
prevented apoptosis and preserved tubular integrity[10]. Since the severity of AKI appears to
be a strong predictor of CKD progression[21,22], we sought to evaluate the impact of L-Arg
supplementation during the progression of AAN using our mouse model that has now been
described as a useful tool considering the gradual progression from acute to chronic injury
[23]. Indeed, NO might act as a key factor on both renal function and fibrosis development
[20].
Materials and methods
Experimental protocol
The study conformed to APS’s guiding principles in the Care and Use of Animals and was
approved by the Animal Ethics Committee of the University of Namur (approval number:
15247). Experiments were performed on 8 weeks-old C57Bl/6J male mice (Janvier, France).
Mice were randomly subjected to daily intraperitoneal (i.p.) injection of either vehicle solution
or aristolochic acid I (AAI) solution (3,5 mg/Kg b.w.; Sigma-Aldrich, USA) for 4 days. L-Argi-
nine (5%; Sigma-Aldrich, USA) was supplemented in drinking water 7 days before the begin-
ning of either vehicle or AAI of i.p. injections, until the end of the experimental protocol. The
estimated dose of L-Arg was about 12 mg/g b.w. per day. Experimental groups were estab-
lished as followed:
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- Mice from CTL group (n = 24) received daily i.p. injections of vehicle solution;
- Mice from L-Arg group (n = 24) received daily i.p. injections of vehicle solution and L-Arg in
drinking water;
- Mice from AA group (n = 24) received daily i.p. injections of AAI solution;
- Mice from AA+L-Arg group (n = 24) received daily i.p. injections of AAI solution and L-Arg
in drinking water.
Body weight was measured daily in order to assess health of the mice and to adjust the drug
dosages. In each group, following a 24-h period in a metabolic cage to collect urine, mice were
anesthetized with a solution of ketamine (Nimatek1, Eurovet Animal Health, Netherlands, 80
mg/Kg b.w.) and medetomidine (Domitor1, Orion Pharma, Finland, 0.5 mg/Kg b.w.) and
then killed by intracardiac puncture and therefore exsanguination either at 5 (n = 8), 10
(n = 8) or 20 days (n = 8) after the first i.p. injection of vehicle or AAI. Blood sample was col-
lected by cardiac puncture, both kidneys were excised and immediately processed for further
analyses. In order to avoid the multiplication of figures in this manuscript, we decided to not
illustrate L-Arg group since L-Arg impact on control mice as already been demonstrated by
our group in a previous study [10]. Indeed, in control condition, L-Arg treatment had no
impact on all parameters except for urinary NOx level that was significantly increased at Day 5
and Day 20 compared to control mice. A significant increase in urinary cGMP level at Day 10
compared to control mice was also demonstrated. In contrast, eNOS, iNOS and nNOS mRNA
expressions were unchanged with L -Arg treatment in control mice compared to the control
group without L -Arg treatment (S1 Fig).
Determination of NO bioavailability
Concentrations of NO2/NO3 metabolites and cGMP were measured in urine samples using
colorimetric assays (Cayman Chemical Company, USA) as previously described [10].
Measurement of urinary and plasma markers
Blood samples were centrifuged at high speed for 10 min at 4˚C. Plasma was collected and fro-
zen at − 80˚C until use. Plasma creatinine concentration was determined using a sensitive
accurate HPLC method (Spherisorb5-μm SCX column, 4.0 × 250 mm; Waters, USA). Blood
urea nitrogen was measured using a colorimetric assay (BioAssay Systems, USA) following the
manufacturer’s protocol. Urinary protein levels were assayed according to the Bradford
method using bovine serum albumin as a standard.
Renal histology
Periodic acid–Schiff staining (PAS). Tissue samples were fixed in Duboscq-Brazil fluid
and embedded in paraffin. Five-μm sections were prepared and exposed to Schiff’s reagent to
perform PAS staining in order to highlight renal damages. Tubular injury scoring was assessed
on kidney sections. For each sample, 10 consecutive fields were analysed at a magnification of
200× and were considered positive for injury based on the presence of tubular necrosis or atro-
phy, luminal casts and alterations in the brush border. Tubular injury was expressed as a
percentage.
Sirius Red staining. To assess collagen I and III deposits, 5-μm sections were stained with
picrosirius red (Sirius Red).
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Immunohistochemistry
Immunohistochemical detection of macrophages, lymphocytes and myofibroblasts (using α-
SMA) was performed on paraffin-embedded kidney sections. Briefly, after dewaxing and rehy-
dration, a microwave pre-treatment in citrate buffer (pH 6.2) was performed to unmask anti-
gens present in the renal tissue. Tissue sections were then incubated for 1 h with primary
antibodies: anti-macrophages (rat anti-mouse F4/80 antibody, Abcam, UK), anti-lymphocytes
(rabbit anti-mouse CD3 antibody, Abcam, UK) and anti-α-SMA (rabbit anti-mouse antibody,
Abcam, UK). After rinsing in PBS, slides were exposed for 30 min to the appropriate second-
ary antibody. Kidney sections were finally incubated with ABC complex (Vector Laboratories,
UK) for 30 min and bound peroxidase activity was detected with the DAB kit (DAKO, Bel-
gium). Counterstaining was performed with hemalun and Luxol fast blue.
Morphometric analysis in the renal tissue
The relative area occupied by α-SMA staining and Sirius Red in the renal tissue was evaluated
by a computer-assisted morphometric approach as previously described [24]. Evaluation of
the relative positive area was performed on one section per experimental animal. For each sec-
tion, 10 square fields (0.084 mm2/field) were observed at 400x magnification in each renal
zone. The relative area occupied by the positive staining was expressed as a percentage.
Cell counts
The frequency of macrophage-positive cells and lymphocyte-positive cells in the interstitium
was evaluated by a semi-quantitative analysis. Briefly, the distribution of positive cells was per-
formed on one section per experimental animal. For each section, 10 square fields (0.084
mm2/field) were observed at 400× magnification. Quantifications were performed by two
investigators blind to the group origin of the mouse.
Quantitative real-time PCR
Frozen kidneys were homogenized and total RNA was then extracted with Trizol (Sigma-
Aldrich, USA) and treated with DNAse (Promega, Belgium). Total RNA concentration was
measured by NanoDrop (NanoDrop 1000, Thermo Scientific, USA). Transcript-specific prim-
ers were generated on the basis of mouse sequences from GenBank. NCBI Primer Blast was
used to ensure specificity of primers for each target. All pairs of primers were analysed for dis-
sociation curves and melting temperatures. Real-time quantitative PCR was performed in
order to quantify mRNA level of eNOS, iNOS, nNOS, IL-1β, IL-6, TNFα, Col I, Col III, CTGF,
Periostin, TGFβ, Smad3 and 18S as a housekeeping gene (see Table 1). Briefly, 2 μg of total
RNA were used for reverse transcription using MLV reverse transcriptase (Promega, Belgium)
during 1 h at 70˚C. Quantitative PCR amplification was performed using the SYBR Green
Master Mix (Roche, Belgium) and the Prism 7300 Real-Time PCR Detection System (Applied
Biosystems, CA, USA). Mean fold changes were calculated by averaging the duplicate mea-
surement for each gene. Relative gene expressions were calculated using the 2−ΔΔCT method.
Statistics
Results are presented as mean values ± SEM. Statistical group analysis was performed with Sig-
maStat 11.0 (Systat Software, San Jose, CA, USA). Comparisons between groups were evalu-
ated by two-way ANOVA. Significant analysis of variance was followed by the Holm-Sidak
multiple-comparisons procedure. A P-value < 0.05 was considered statistically significant.
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Results
L-arginine supplementation prevents the decrease in NO bioavailability
As shown in Fig 1A and 1B, AA treatment induced a significant decrease in urinary concentra-
tions of NO metabolites (NOx) and cGMP throughout the experimental protocol, that were
prevented by L-Arg treatment. Intrarenal expression of eNOS, iNOS and nNOS was measured
in all group of mice, using quantitative RT-PCR analysis. Renal expression of eNOS mRNA
(Fig 1C) in mice treated either with AA or with AA and L-Arg did not differ compared to CTL
mice. An increase of iNOS mRNA (Fig 1D) expression was observed at day 20 in AA treated
mice (2.42 ± 0.26, P<0.009) as well as in AA+L-Arg mice (2.54 ± 0.61, P<0.005) compared to
CTL (0.94 ± 0.25). A slight increase of nNOS mRNA (Fig 1E) expression was also observed in
AA mice as well as in AA+L-Arg mice all along the protocol.
Effect of L-arginine supplementation on renal function
To better characterize the effect of L-Arg supplementation on renal function in AA-treated
mice, urinary and plasma markers of renal function were measured. As shown in Table 2, AA
mice displayed polyuria at day 10 (1.35 ± 0.17 ml.24h-1, P<0.012) and at day 20 (2.02 ± 0.28
Table 1. Sequences of the primers used for qRT-PCR.
Gene Primer Sequences (5’-3’)
eNOS F AACCATTCTGTATGGCTCTGAGAC
R CTCTAGGGACACCACATCATACTC
iNOS F CAGCTGGGCTGTACAAACCTT
R ATGTGATGTTTGCTTCGGACA
nNOS F ACCCTGTGCGAGATCTTCAA
R TGGTGACCACCAAGACCAG
NGAL F ATGTCACCTCCATCCTGGTC
R CCTGTGCATATTTCCCAGAGT
IL-1β F AGTTGACGGACCCCAAAAG
R AGCTGGATGCTCTCATCAGG
IL-6 F GCTACCAAACTGGATATAATCAGGA
R CCAGGTAGCTATGGTACTCCAGAA
TNFα F TACTGAACTTCGGGGTGATTGGTCC
R CAGCCTTGTCCCTTGAAGAGAACC
Col I F GCAGGTTCACCTACTCTGTCCT
R CTTGCCCCATTCATTTGTCT
Col III F TCCCCTGGAATCTGTGAATC
R TGAGTCGAATTGGGGAGAAT
CTGF F TGACCTGGAGGAAAACATTAAGA
R AGCCCTGTATGTCTTCACACTG
Periostin F TCGTGGAACCAAAAATTAAAGTC
R CTTCGTCATTGCAGGTCCTT
TGFβ F TGGAGCAACATGTGGAACTC
R GTCAGCAGCCGGTTACCA
Smad3 F GCCACTGTCTGCAAGATCC
R AGCTAGGAGGGCAGCAAAT
18S F CGCCGCTAGAGGTGAAATTCT
R CGAACCTCCGACTTTCGTTCT
https://doi.org/10.1371/journal.pone.0183604.t001
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ml.24h-1, P<0.001) after AA intoxication compared to CTL mice (0.59 ± 0.13 ml.24h-1 and
0.79 ± 0.20 ml.24h-1, respectively). In L-Arg-treated mice, polyuria was prevented at day 10
(0.67 ± 0.13 ml.24h-1, P<0.013). At day 20, even though the polyuria was significantly lower
than in mice only treated with AA (P<0.023), it remains still significantly higher compared to
Fig 1. Urinary NOx and cGMP excretions at days 5, 10 and 20 in CTL, AA and AA+L-Arg mice and relative kidney expression of
nitric oxide synthases mRNA (2-Δ ΔCT) at days 5, 10 and 20 in CTL, AA and AA+L-Arg mice. (A) Urinary nitrite/nitrate (NOx)
concentrations in CTL, AA and AA+L-Arg mice. (B) Urinary cGMP concentrations in CTL, AA and AA+L-Arg mice. Real-time quantitative
PCR for endothelial nitric oxide synthase (eNOS) (C), inducible nitric oxide synthase (iNOS) (D) and neuronal nitric oxide synthase (nNOS)
(E) mRNA expression was performed on kidney tissue from CTL, AA and AA+L-Arg mice normalized against 18S. Data are presented as
means ± SEM; n = 8 in each group. Statistical analysis were performed by two-way ANOVA followed by Holm-Sidak test. *P 0,05 vs CTL
mice, **P 0,01 vs CTL mice, ## P 0,01 vs AA mice.
https://doi.org/10.1371/journal.pone.0183604.g001
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CTL mice (1.43 ± 0.19 ml.24h-1, P<0.028). AA intoxication also induced an increase in plasma
creatinine (PCr) and blood urea nitrogen (BUN) that reached a maximum level at day 10.
These changes were partially prevented by L-Arg supplementation at this timepoint.
L-arginine supplementation reduces tubular injury
To characterize the effect of L-Arg supplementation on tubular injury, a morphological analy-
sis was performed along with the measurement of NGAL mRNA expression, a marker of tubu-
lar injury. As illustrated in Fig 2, CTL mice displayed normal renal structures (Fig 2A, 2D and
2G). At day 5 (Fig 2B), AA treatment induced necrosis of PTEC, tubular cell detachment, with
the presence of cell debris in tubular lumens in the outer stripe of outer medulla (OSOM),
with some extension to the cortex. A similar pattern was observed in AA+L-Arg mice but at a
lesser extend as attested by the decreased tubular injury percentage (30 ± 3% for AA mice and
18 ± 3% for AA+L-Arg mice, P<0.006). Histological analysis of kidney sections from AA and
AA+L-Arg at day 10 (Fig 2E and 2F) revealed appearance of atrophic tubules along with per-
sistence of necrotic tubule area. At that time-point, L-Arg treatment did not significantly
decrease the tubular injury score (Fig 2K). Finally, at day 20, numerous atrophic tubules were
detected in AA-treated mice and AA+L-Arg-treated mice. Interestingly, L-Arg-treated mice
presented a slight decrease of tubular injury (44 ± 2% for AA mice and 36 ± 2% for AA+L-Arg
mice, P<0.032). The results of this morphological analysis were correlated with NGAL mRNA
expression. Indeed, a significant increase of mRNA expression levels of NGAL was observed in
AA-treated mice at day 10 and day 20 of the protocol that was attenuated at both time-points
with L-Arg supplementation (Fig 2J).
Table 2. Effect of L-arginine supplementation on renal function at days 5, 10 and 20 in CTL, AA and AA+L-Arg mice.
Diuresis–ml.24h-
1
Creatinine clearance–ml.
min-1
Plasma creatinine level–
μmol.l-1
Blood urea nitrogen– μmol.
l-1
Proteinuria–mg.mg
Cre-1
Day 5
CTL 0.43 ± 0.10 1.29 ± 0.10 3.51 ± 0.27 11.31 ± 1.15 5.31 ± 0.18
AA 0.45 ± 0.21 0.15 ± 0.02 *** 12.01 ± 2.28 9.16 ± 1.44 16.09 ± 3.71 ***
AA
+ L-Arg
0.45 ± 0.12 1.12 ± 0.35 ## 5.95 ± 1.31 7.55 ± 1.90 10.41 ± 2.51
Day 10
CTL 0.59 ± 0.13 1.02 ± 0.16 4.02 ± 0.63 11.07 ± 1.46 5.45 ± 1.02
AA 1.35 ± 0.17 * 0.29 ± 0.09 *** 27.29 ± 5.25 *** 183.10 ± 41.72 *** 14.28 ± 2.67 **
AA
+ L-Arg
0.67 ± 0.13 # 1.41 ± 0.43 ### 3.72 ± 1.01 ### 100.80 ± 30.81 * ## 12.08 ± 1.34 *
Day 20
CTL 0.79 ± 0.20 1.11 ± 0.19 3.91 ± 0.63 11.65 ± 1.42 6.92 ± 0.37
AA 2.02 ± 0.28 *** 0.57 ± 0.11 17.06 ± 3.11 ** 100.80 ± 18.60 11.01 ± 0.96
AA
+ L-Arg
1.43 ± 0.19 * # 0.47 ± 0.04 12.52 ± 1.56 111.30 ± 17.10 11.87 ± 0.51
Statistical analysis was performed using two-way ANOVA followed by Holm-Sidak test. Data are presented as means ± SEM; n = 8 in each group.
*P 0,05 vs CTL mice,
**P 0,01 vs CTL mice,
***P 0,001 vs CTL mice,
#P  0,05 vs AA mice,
##P 0,01 vs AA mice
###P 0,001 vs AA mice.
https://doi.org/10.1371/journal.pone.0183604.t002
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Fig 2. Effect of L-arginine supplementation on tubular injury score and on relative kidney expression of Neutrophil Gelatinase-
Associated Lipocalin (NGAL) mRNA at days 5, 10 and 20 in CTL, AA and AA+L-Arg mice. Tubular injury in CTL, AA and AA+L-Arg
mice. Representative photographs of hemalun, Luxol fast blue and Periodic Acid Schiff stained kidney sections (x400) from CTL (A,D,G),
AA (B,E,H) and AA+L-Arg (C,F,I) mice at days 5, 10 and 20. Necrotic tubules (red) with cell debris in tubular lumens are visible in AA and
AA+L-Arg treated mice at days 5 and 10 and cystic tubules (green) are visible in AA and AA+L-Arg treated mice at days 10 and 20. Scale
bar = 50 μm. Real-time quantitative PCR for Neutrophil Gelatinase-Associated Lipocalin (NGAL) mRNA expression was performed with
kidney tissue from CTL, AA and AA+L-Arg mice normalized against 18S (J). Quantitative analysis of tubular injury in CTL, AA and AA
+L-Arg mice at days 5, 10 and 20 (K). Statistical analysis was performed using two-way ANOVA followed by Holm-Sidak test. Data are
presented as means ± SEM; n = 8 in each group. ***P 0,001 vs CTL mice, #P 0,05 vs AA mice, ##P 0,05 vs AA mice and
###P 0,001 vs AA mice.
https://doi.org/10.1371/journal.pone.0183604.g002
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L-arginine supplementation reduces inflammation
Since cytokines are critical factors determining the inflammatory response during the progres-
sion to CKD, we performed quantitative RT-PCR analysis to evaluate their involvement during
the time-course of our model. As shown in Fig 3A, intrarenal IL6 mRNA was highly upregu-
lated throughout the protocol in AA-treated mice, with the highest over-expression measured
at 5 days after AAN induction (nearly 120-fold increase relative to control). L-Arg treatment
significantly reduced this upregulation at day 5 and day 10. Expression of IL1β mRNA (Fig 3B)
was also significantly increased throughout the protocol in AA-treated mice to reach a highest
level at day 20 (8.10 ± 0.69 fold increase relative to control). This upregulation was significantly
reduced with L-Arg treatment at day 10 and day 20. A similar pattern was observed for mRNA
expression of TNFα (Fig 3C) that reached 14.60 ± 2.02 fold increase relative to control at day
20. A significant reduction of TNFα mRNA expression was also revealed after L-Arg treatment
at day 10 and day 20 in AA-treated mice. Finally, interstitial macrophages (F4/80—positive
cells, Fig 3D) were accumulated in the kidney tissue of AA-treated mice throughout the proto-
col with a significant amount at days 10 and day 20. This process was prevented by L-Arg treat-
ment at both time-points. In addition, significant accumulation of interstitial lymphocytes
(CD3—positive cells, Fig 3E) observed at day 20 in AA-treated mice was significantly reduced
by L-Arg supplementation.
L-arginine supplementation reduces fibrosis
Since progressive tubulointerstitial fibrosis is a sign of progressive ESRD, specific markers of
renal fibrosis were investigated. Collagen deposition was studied by morphometric analysis in
Sirius red-stained renal sections as an index of the fibrotic response. As illustrated in Fig 4B,
4E and 4H, collagen I and III were accumulated in the interstitium of AA-treated mice from
day 10 and even enhanced at day 20, reflecting the progression to chronic injury. This observa-
tion was confirmed by the quantitative analysis of Sirius Red positive staining (Fig 4L) as well
as by the upregulation of Col I and Col III mRNA expression (Fig 4J and 4K). L-Arg treatment
significantly reduced collagen I and III deposition (Fig 4C, 4F, 4I and 4L) as well as the upregu-
lation of Col I and Col III mRNA expression (Fig 4J and 4K). Moreover, the increase in α-SMA
expression, reflecting the amount of myofibroblasts in the renal interstitium, observed at 10
and 20 days after AA intoxication was also completely prevented by L-Arg treatement (Fig 5).
The quantitative RT-PCR measurement of the AA-induced expression of CTGF, TGFβ, Perios-
tin and Smad3 all considered as key profibrotic markers (Fig 6), demonstrated their significant
increase with the AA treatment at day 10 and day 20. These upregulations were significantly
reduced with L-Arg treatment.
Discussion
Since the identification of AA toxicity in Belgium in 1992[25], experimental in vitro and in
vivo models have been developed and studies have been undertaken in order to understand
underlying molecular and cellular mechanisms of AAN pathophysiology. Up to now, the
PTEC have always been reported to be the primary target of AA-induced toxicity[8,9]. How-
ever, only few studies have addressed the involvement of the vascular network and impairment
of vasoactive mediators in AAN pathophysiology[4,10,16,18,26]. In this regard, Depierreux
and colleagues first underlined the issue about the vascular network in AAN pathology[4].
Since then, decrease in peritubular capillaries has been described[26,27] associated to a
reduced expression of vascular endothelial growth factor (VEGF) along with an increased
expression of hypoxia inducible factor-1 (HIF-1). These observations suggested that ischemia
and hypoxia could contribute to AAN progression[27]. Similar data, reported by Wen et al.,
Nitric oxide in aristolochic acid induced AKI-to-CKD transition
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Fig 3. Effect of L-arginine supplementation on relative kidney expression of inflammatory cytokines; interleukin 6 (IL6),
interleukin 1β (IL1β) and tumor necrosis factor α (TNFα) mRNA (2-Δ ΔCT) and on on interstitial infiltration of macrophages and
lymphocytes at days 5, 10 and 20 in CTL, AA and AA+L-Arg mice. Real-time quantitative PCR for interleukin 6 (IL6) (A), interleukin 1β
(IL1β) (B) and tumor necrosis factor α (TNFα) (C) mRNA expression was performed on kidney tissue from CTL, AA and AA+L-Arg mice
normalized against 18S. Macrophage (D) and lymphocyte (E) accumulation within the interstitium of kidney from CTL, AA and AA+L-Arg
mice at days 5, 10 and 20. Statistical analysis was performed using two-way ANOVA followed by Holm-Sidak test. Data are presented as
means ± SEM; n = 8 in each group. *P 0,05 vs CTL mice, **P 0,01 vs CTL mice, ***P 0,001 vs CTL mice, #P 0,05 vs AA mice,
##P 0,01 vs AA mice and ###P 0,001 vs AA mice.
https://doi.org/10.1371/journal.pone.0183604.g003
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Fig 4. Effect of L-arginine supplementation on Sirius Red staining at days 5, 10 and 20 in CTL, AA and AA
+L-Arg mice. Representative photographs of picrosirius red stained kidney sections (x400) from CTL (A,D,G), AA
(B,E,H) and AA+L-Arg (C,F,I) mice at days 5, 10 and 20. Scale bar = 50 μm. Real-time quantitative PCR for ColI
(J) and ColIII (K) mRNA expression was performed with kidney tissue from CTL, AA and AA+L-Arg mice
normalized against 18S Quantitative analysis of picrosirius red expression in CTL, AA and AA+L-Arg mice at days
5, 10 and 20 (L). Statistical analysis was performed using two-way ANOVA followed by Holm-Sidak test. Data are
presented as means ± SEM; n = 8 in each group. **P 0,01 vs CTL mice, ***P 0,001 vs CTL mice, #P 0,05
vs AA mice, ##P 0,01 vs AA mice and ###P 0,001 vs AA mice.
https://doi.org/10.1371/journal.pone.0183604.g004
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revealed an imbalance between vasoactive factors with a reduced NO production, while
expression of endothelin-1 (ET-1) was increased in a rat model of AAN[16]. Since the kidney
is characterized by a high energy demand, this organ is very susceptible to further compromise
of vascular perfusion and oxygenation[28]. Although it is well known that injury of renal
Fig 5. Effect of L-arginine supplementation on α-SMA expression at days 5, 10 and 20 in CTL, AA and AA+L-Arg mice.
Representative photographs of α-SMA immunostained kidney sections (x400) from CTL (A,D,G), AA (B,E,H) and AA+L-Arg (C,F,I)
mice at days 5, 10 and 20. Scale bar = 50 μm. Quantitative analysis of α-SMA expression in CTL, AA and AA+L-Arg mice at days 5,
10 and 20 (J). Statistical analysis was performed using two-way ANOVA followed by Holm-Sidak test. Data are presented as
means ± SEM; n = 8 in each group. ***P 0,001 vs CTL mice and ###P 0,001 vs AA mice.
https://doi.org/10.1371/journal.pone.0183604.g005
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microvasculature, endothelial cell activation as well as imbalance between vasoactive sub-
stances widely contributes to the progression from AKI to CKD[28–31], these mechanisms
remain poorly investigated in AAN pathogenesis.
In the kidney, NO plays major roles in the regulation of vascular resistance, glomerular fil-
tration rate, water and sodium excretion, and in the maintenance of renal structural integrity
[19]. In most kidney diseases, renal NO level is reduced which could contribute to further pro-
gression to CKD and ESRD[20,32]. In this regard, L-Arg supplementation was found to play a
protective role by improving renal function in in vivo models of nephrotoxicity as induced by
cisplatin[33], cyclosporine[34,35] and gentamicin[36]. Conversely, chronic administration of
a non-selective inhibitor of NOSs, L-NAME (N-nitro-L-Arg methyl ester) leads to worsening
of renal injury in the same models[33,35,36].
In view of these elements, our group investigated for the first time NO involvement in a
mouse model of AAN[10]. In this previous study, we established a reduction in NO bioavail-
ability in mice intoxicated with AA, occurring as soon as five days after the beginning of the
AA intoxication. This effect was associated with a decrease of the renal function, massive
necrosis of PTEC, increased inflammation and oxidative stress. We then demonstrated that
restoring renal NO bioavailability through L-Arg supplementation reduced oxidative stress,
improved renal function and preserved renal structure[10]. These data may lead to consider
Fig 6. Effect of L-arginine supplementation on relative kidney expression of profibrotic factors; connective tissue
growth factor (CTGF), transforming growth factor β (TGFβ), periostin and Smad3 mRNA (2-Δ ΔCT) at days 5, 10 and 20 in
CTL, AA and AA+L-Arg mice. Real-time quantitative PCR for CTGF (A), TGFβ (B), Periostin (C) and Smad3 (D) mRNA
expression was performed with kidney tissue from CTL, AA and AA+L-Arg mice normalized against 18S. Statistical analysis was
performed using two-way ANOVA followed by Holm-Sidak test. Data are presented as means ± SEM; n = 8 in each group.
*P 0,05 vs CTL mice, ***P 0,001 vs CTL mice, #P 0,05 vs AA mice, ##P 0,01 vs AA mice and ###P 0,001 vs AA mice.
https://doi.org/10.1371/journal.pone.0183604.g006
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that impairment of vasoactive mediators such as NO constitutes an early event of the disease,
suggesting that impairment of the vascular compartment contributes to progression to later
stage.
In the present study, we extended our investigation to the progression from AKI to CKD in
our AAN model. We demonstrated for the first time that reduction in NO bioavailability plays
a crucial role in AA-induced AKI-to-CKD transition. Indeed, L-Arg supplementation shows
nephroprotective effects by reducing the severity of the transition from AKI to CKD and most
importantly, by reducing fibrosis development.
Firstly, our results confirmed the reduction of urinary NOx metabolites and cGMP levels
reflecting a decreased renal NO bioavailability in our AAN model throughout the experimen-
tal protocol. L-Arg supplementation allowed to restore renal NO levels as already described by
our group[10] as well as in other models of nephrotoxicity[33,35,37].
AA nephrotoxicity was demonstrated by polyuria and a marked increase in plasma creati-
nine and BUN. Oral administration of L-Arg to AA-treated mice resulted in complete normal-
ization of plasma creatinine level and significantly reduced BUN level. These data support
previous findings reporting similar effects in cisplatin and cyclosporine models[33–36] thereby
highlighting the protective role of L-Arg supplementation. Histological examination of kidney
sections confirmed the occurrence of renal damage as attested by histopathological features of
AAN observed in our model. At first, tubular necrosis occurs in the early phase of AKI, leading
to development of chronic lesions such as tubular atrophy and interstitial fibrosis observed in
the later phase. Treatment with L-Arg improved the pathological changes induced by AA
treatment as also reported in the cisplatin and cyclosporine nephrotoxicity model[33,35].
It is well established that after an episode of AKI, persistent maladaptive repair mechanisms
promote inflammation. In the present study, renal mRNA expression of pro-inflammatory
cytokines, IL-6, IL-1β and TNF-α, was increased following AA treatment as also observed in
cisplatin-induced nephrotoxicity[38]. With L-Arg treatment, the mRNA upregulation of these
cytokines was significantly dampened. Macrophages are key regulators of inflammation and
fibrosis[39]. Although it does not prove causality, it has been reported that the number of
interstitial macrophages was closely correlated with interstitial fibrosis, atrophic tubules,
reduced capillary density, and decreased renal survival[28]. In our study, L-Arg supplementa-
tion reduced renal inflammatory injury as attested by decreased macrophages and lymphocytes
infiltration as previously reported in the literature in a rat model of obstructive nephropathy
and puromycin-induced nephrosis[40]. Moreover, it has been recently shown that different
subpopulations of macrophages may play specific roles in the course from AKI to CKD[39].
These findings underscore the urgent need of understanding macrophage function and charac-
terizing these subpopulations as well as their specific role in the pathogenesis of AAN.
The most striking feature reported in AAN is an extensive interstitial fibrosis[4]. Here, our
results demonstrate that L-Arg treatment reduced collagen accumulation as already described
in other models of kidney disease[37,41]. Since endothelial dysfunction may be considered as
an important factor in progression of renal fibrosis, NO might play a key role by controlling
extracellular matrix synthesis during fibrogenesis[42,43]. Interestingly, accumulation of asym-
metric dimethylarginine (ADMA), an endogenous NOS inhibitor, in the plasma of patients
suffering from CKD[20,44], has been reported and proposed to contribute to endothelial dys-
function during fibrosis development[44], thereby confirming that NO plays a central role in
fibrogenesis. Indeed, NO is directly linked to the TGF-β pathway since ADMA administration
in mice was associated with a strong induction of mRNA and protein expression of TGF-β
[44]. In our study, we were able to confirm this crosstalk since L-Arg supplementation partially
prevented AA-induced TGF-β mRNA upregulation as also reported in a rat model of unilateral
ureteral obstruction[41]. Moreover, we also confirmed that downregulation of Smad3
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protected mice from chronic AAN as reported by Zhou and collaborators [45] and that block-
ade of the TGF- β/Smad3 signaling pathway may have therapeutic potential for prevention of
treatment of chronic AAN. We also established for the first time that Periostin mRNA is over-
expressed in AAN. This result is not surprising since, in addition of being a marker of progres-
sion of renal fibrosis, periostin has been reported to mediate renal disease through interaction
with the TGF-β pathway[46]. This effect of periostin might therefore explain the similar pat-
tern of TGF-β and Periostin mRNA expression observed throughout our protocol. Finally, the
degree of fibrotic response is strongly linked to the degree of the inflammatory response. We
can therefore postulate that some beneficial effects of NO on reducing renal fibrosis are related
to attenuation of inflammatory cells infiltration as discussed in the previous section (S2 Fig).
Based on our results, we reported for the first time that L-Arg supplementation may reduce
interstitial fibrosis development in a mouse model of AAN. Mechanisms by which L-Arg
exerts its protection against AA-induced nephrotoxicity remain speculative but some hypothe-
ses can nevertheless be proposed. Until now, PTEC have always been considered as the pri-
mary target of AA-induced toxicity[8,9,47]. However, only few studies have addressed the
involvement of the vascular network in AAN pathophysiology[4,12,16]. Nowadays, it is recog-
nized in the literature that altered renal hemodynamics widely contribute to ongoing hypoxia
and to the transition from AKI to CKD[28]. Therefore, we postulate that imbalance between
endothelial vasoactive agents could contribute to renal dysfunction and, therefore, to fibrosis
development in AAN. In this regard, L-Arg mediated protection should, at least in part, be due
to restoration of NO deficiency thereby limits hypoxic injury to the kidney. Schneider et al[48]
also proposed that L-Arg treatment could also overcome the accumulation of ADMA in their
ischemic rat model. Moreover, protection could also come from additional non-hemodynamic
cytoprotective effects. Indeed, L-Arg has already been shown to prevent the rise in lipid perox-
ides and the decrease in glutathione peroxidase activity, as induced in cyclosporine and in cis-
platine treated rats[33,49]. We also previously reported that L-Arg reduces Nox2 mRNA
expression and ROS production in our AAN model, thereby decreasing AA-induced oxidative
stress[10]. In this study, we confirmed that L-Arg decreases renal Nox2 mRNA expression as
well as NRF-2 and HO-1 mRNA expression (S3 Fig). Besides, the data obtained from our study
may not exclude the possibility of the involvement of some L-Arg metabolites in this protective
effect. In this regard, conversion to agmatine or stimulation of glucagon secretion could also
be involved[50]. Nevertheless, we can reasonably confirm the involvement of NO considering
the numerous studies reporting aggravated renal dysfunction and histopathological alterations
after NO synthesis inhibition[33,35,36].
In conclusion, the present study brings further support to the role of NO in modulating
nephrotoxicity and highlights the anti-inflammatory and anti-fibrotic properties of L-Arg sup-
plementation in the evolution of AAN. The decrease in renal NO bioavailability contributes, at
least in part, to the mechanism underlying the progression from AKI to CKD in AA-induced
nephrotoxicity. Therefore, L-Arg seems to represent a promising agent in reducing renal
inflammation and fibrosis occurring after acute or chronic intoxications.
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dase 2 (NOX2), NADPH oxidase 4 (NOX4), nuclear factor erythroid 2–related factor 2
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